JP2023538125A5 - - Google Patents
Info
- Publication number
- JP2023538125A5 JP2023538125A5 JP2023512428A JP2023512428A JP2023538125A5 JP 2023538125 A5 JP2023538125 A5 JP 2023538125A5 JP 2023512428 A JP2023512428 A JP 2023512428A JP 2023512428 A JP2023512428 A JP 2023512428A JP 2023538125 A5 JP2023538125 A5 JP 2023538125A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- gsi
- semagacestat
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063068235P | 2020-08-20 | 2020-08-20 | |
| US63/068,235 | 2020-08-20 | ||
| PCT/US2021/046742 WO2022040447A2 (en) | 2020-08-20 | 2021-08-19 | Methods for treating respiratory diseases characterized by mucus hypersecretion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023538125A JP2023538125A (ja) | 2023-09-06 |
| JP2023538125A5 true JP2023538125A5 (enExample) | 2024-08-20 |
Family
ID=80323184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512428A Pending JP2023538125A (ja) | 2020-08-20 | 2021-08-19 | 粘液過剰分泌を特徴とする呼吸器疾患を処置するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230277550A1 (enExample) |
| EP (1) | EP4199914A4 (enExample) |
| JP (1) | JP2023538125A (enExample) |
| KR (1) | KR20230052954A (enExample) |
| CN (1) | CN116033895A (enExample) |
| AU (1) | AU2021329507A1 (enExample) |
| BR (1) | BR112023002651A2 (enExample) |
| CA (1) | CA3188234A1 (enExample) |
| IL (1) | IL300405A (enExample) |
| MX (1) | MX2023001993A (enExample) |
| WO (1) | WO2022040447A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4268824A1 (en) * | 2022-04-26 | 2023-11-01 | Manros Therapeutics | Imidazo[2,1-f][1,2,4]triazine derivatives useful as a medicament |
| WO2024112356A1 (en) * | 2022-11-23 | 2024-05-30 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating respiratory diseases characterized by mucus hypersecretion |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7468365B2 (en) | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
| SE0101004D0 (sv) | 2001-03-21 | 2001-03-21 | Astrazeneca Ab | New measuring technique |
| LT2502911T (lt) | 2004-06-24 | 2017-09-11 | Vertex Pharmaceuticals Incorporated | Atp surišančios kasetės transporterių moduliatoriai |
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| CA2644136A1 (en) * | 2006-02-27 | 2007-09-07 | The Johns Hopkins University | Cancer treatment with gamma-secretase inhibitors |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| NZ571803A (en) | 2006-04-07 | 2011-12-22 | Vertex Pharma | Amide indole derivatives as modulators of ATP-binding cassette transporters |
| SI2225230T1 (sl) | 2007-12-07 | 2017-03-31 | Vertex Pharmaceuticals Incorporated | Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline |
| US8299059B2 (en) | 2009-10-30 | 2012-10-30 | Eli Lilly And Company | Crystalline compound and a process for its preparation |
| HUE040366T2 (hu) | 2013-08-08 | 2019-03-28 | Galapagos Nv | CFTR modulátor tieno[2,3-c]piránok |
| EP2932966A1 (en) * | 2014-04-16 | 2015-10-21 | Novartis AG | Gamma secretase inhibitors for treating respiratory diseases |
| TWI735416B (zh) | 2014-10-06 | 2021-08-11 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| CA2971850A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| MA42488A (fr) | 2015-07-24 | 2018-05-30 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| CA3000483C (en) | 2015-10-06 | 2024-02-13 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
| US9890149B2 (en) | 2015-10-07 | 2018-02-13 | NuBridge BioSciences | Isothiazole derivatives as CFTR modulators |
| RU2724345C2 (ru) | 2015-10-09 | 2020-06-23 | Галапагос Нв | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
| AU2017256172A1 (en) | 2016-04-26 | 2018-09-06 | AbbVie S.à.r.l. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
| US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| AU2017362350B2 (en) | 2016-11-18 | 2021-12-23 | Cystic Fibrosis Foundation | Pyrrolopyrimidines as CFTR potentiators |
| US10131670B2 (en) | 2016-12-16 | 2018-11-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Bicyclic heteroaryl derivatives as CFTR potentiators |
| MX2019009552A (es) * | 2017-02-17 | 2019-10-02 | Hutchinson Fred Cancer Res | Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios. |
| TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
| PL4010322T3 (pl) | 2019-08-09 | 2026-02-16 | Pfizer Inc. | Stałe postacie (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaftalen-2-ylo)amino)-n-(1-(2-metylo-1-(neopentyloamino)propan-2-ylo)-1h-imidazol-4-ilo)pentanamidu i ich zastosowanie |
-
2021
- 2021-08-19 KR KR1020237009414A patent/KR20230052954A/ko active Pending
- 2021-08-19 US US18/018,999 patent/US20230277550A1/en active Pending
- 2021-08-19 CN CN202180051358.5A patent/CN116033895A/zh active Pending
- 2021-08-19 IL IL300405A patent/IL300405A/en unknown
- 2021-08-19 MX MX2023001993A patent/MX2023001993A/es unknown
- 2021-08-19 BR BR112023002651A patent/BR112023002651A2/pt unknown
- 2021-08-19 JP JP2023512428A patent/JP2023538125A/ja active Pending
- 2021-08-19 CA CA3188234A patent/CA3188234A1/en active Pending
- 2021-08-19 EP EP21859146.9A patent/EP4199914A4/en active Pending
- 2021-08-19 WO PCT/US2021/046742 patent/WO2022040447A2/en not_active Ceased
- 2021-08-19 AU AU2021329507A patent/AU2021329507A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023041862A5 (enExample) | ||
| RU2007130700A (ru) | Комбинация соединений метилксантина и стероидов для лечения хронических распираторных заболеваний | |
| JP2023522010A5 (enExample) | ||
| JP2022544711A5 (enExample) | ||
| JP2025092508A5 (enExample) | ||
| EA004657B1 (ru) | Фармацевтическая композиция на основе обладающих антихолинергическим действием соединений , способ ее получения и применение | |
| JP2023076465A5 (enExample) | ||
| JP2023538125A5 (enExample) | ||
| CN102186458A (zh) | 治疗慢性阻塞性肺病及其它肺疾病的方法 | |
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2011173929A (ja) | 呼吸器官の細菌性疾患の処置 | |
| JP2022550919A5 (enExample) | ||
| JP2022520990A (ja) | 呼吸器疾患の治療の方法 | |
| JP2025510096A5 (enExample) | ||
| JP2023523557A5 (enExample) | ||
| SK111894A3 (en) | Pharmaceutical agents for treatment of granulomatese and fibrously pulmonary illnesess | |
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2022526367A5 (enExample) | ||
| US5925625A (en) | Pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
| WO2022040447A3 (en) | Methods for treating respiratory diseases characterized by mucus hypersecretion | |
| FI4199922T3 (fi) | (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa | |
| JP2023519853A5 (enExample) | ||
| MXPA06008240A (es) | Metodos de tratamiento. | |
| JP2021530568A5 (enExample) | ||
| JP2024543259A5 (enExample) |